CONSTELLATION TECHNOLOGIES LIMITED — Interim / Quarterly Report 2013

Jul 22, 2013

23 July 2013

==> picture [114 x 100] intentionally omitted <==

The Manager Company Announcements ASX Limited 20 Bridge Street Sydney NSW 2000 Australia

BY E-LODGEMENT

Dear Sir / Madam

Quarterly Update and Appendix 4C

The attached Appendix 4C lodged today should be read in the context of the following information. This update provides a summary of the Company’s progress towards achieving a number of commercial objectives and its financial position. Agenix's focus is to deliver on our commercialisation milestones, control costs and create long-term shareholder value in a disciplined and strategic manner.

The business has continued to progress and is close to achieving some significant commercialisation milestones. Each of our programs is the subject of active discussions with significant potential commercial partners. We believe achievement of these milestones will continue to strengthen the business.

Rights Issue and Funding Strategy

As of 30 June 2013, the Company's cash balance as shown in the Appendix 4C was $654,000.

The February non-renounceable rights issue for shareholders raised $ 419,396.97 before costs of the offer with all members of the Board taking up their full entitlements.

Page 1 of 3

Quarterly Update and Appendix 4C

Agenix Limited 23 July 2013

All shareholders had the opportunity to participate in the shortfall offer of one share for every share held at an issue price of $0.03 per share together with one free attaching option for every two new shares subscribed.

In May we announced $1 Million of funding with Scintilla Strategic Investments Limited (Scintilla) together with a number of high net worth individuals participating in the shortfall offer. Scintilla is a fund that invests in deep value microcap companies listed on the ASX.

The Rights Issue offer closed on 21 May 2013 fully subscribed and raised $1.235 million. A payment of circa $400,000 was required to be sent to our China operations in order to file the clinical trial application and reimburse costs of those trials. We do not anticipate any further significant cash outflows for this project. A further $200,000 was raised on a zero coupon convertible note with Scintilla and several sophisticated investors.

The funding provides Agenix with the financial resources to complete a number of value accreting milestones. We welcome Scintilla and our new shareholders to the register and appreciate their support of management’s strategy.

EGM

The EGM held on 27 June 2013 overwhelmingly approved and ratified all resolutions put to the meeting with no vote less than 99% in favour. These related to the rights issue, directors accepting shares rather than require repayment of loans to the Company, other parties who have accepted shares rather than cash payments and equity funding facilities.

At the AGM last year, shareholders voted to consolidate the Company’s issued capital on the basis that every 25 shares were consolidated into one share. This consolidation made the raising of further capital possible. Without it, the Company could not have avoided a rather more catastrophic extinguishment of value for all shareholders.

Currently directors and related hold around 22% of the issued capital of the Company, so that our interests are aligned with all shareholders. We believe that the milestones are close and are aware of the consequences of dilution but remain committed to acting in the best interests of all shareholders by maintaining a long term view and a strong balance sheet.

Page 2 of 7

Quarterly Update and Appendix 4C

Agenix Limited 23 July 2013

Appointment of new director

In May the Company announced the appointment of Mr Craig Chapman as a non-executive Director. Craig is a recognised company builder with over 25 years experience across a range of service sectors and has been instrumental in a number of highly successful consolidation plays listed on the ASX including S8 (SEL), Greencross (GXL) and G8 Education (GEM).

Craig has held senior management roles, company secretarial positions and directorships with these companies. He holds a Bachelor of Commerce degree from the University of Queensland and is a CPA. He also holds a Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Secretaries and Administrators.

Craig’s experience in financial markets, management and his professional background will further strengthen our focus on the bottom line and complement our existing expertise.

Pending commercial milestones for all programs

As noted, Agenix is on track to complete a number of important near term milestones.

ThromboView®

Discussions to commercialise our late-stage blood clot diagnostic ThromboView® for its SPECT Phase III trial and commercialisation are continuing. We are also developing the business case for a PET (CT) version of ThromboView® given that a large slice of the diagnostic market has moved in that direction. ThromboView® has multiple advantages compared with the existing standards of care and is positioned to address a major unmet medical need. We know ThromboView® is safe and works and that its market opportunity is large. It is the only functional imaging method for detecting blood clots and has the potential to become the gold standard for diagnosis of pulmonary embolism as well as guide anticoagulation therapy duration.

DiagnostIQ®

At the same time, Agenix is late stage licensing discussions with a partner to develop our recently acquired DiagnostIQ human health platform as a multi-array device. DiagnostIQ has multiple potential licensing opportunities once fully developed as a human health diagnostic platform and our goal is to license the technology and begin generating revenues.

Page 3 of 7

Quarterly Update and Appendix 4C

Agenix Limited 23 July 2013

AGX-1009

Agenix is poised to submit our new drug clinical trial application (CTA) for our proprietary hepatitis B drug AGX-1009 with the China Food and Drug Administration (CFDA) following extensive testing and work with the Institute of Medicinal Biotechnology (IMB) of the Chinese Academy of Medical Sciences and also the Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences in China (AMMS). We have been given no reason not to believe that our application will meet all CFDA requirements and progress to the clinic.

We are also in advanced discussions to partner AGX-1009. This new anti-viral is positioned to meet China's growing demand for effective hepatitis B treatments and by partnering at this stage, the Company will enjoy lower cash burn and strengthen our balance sheet as well as give the project an experienced Chinese partner to conduct clinical trials in patients with chronic hepatitis B who develop resistance to current approved therapies. Our intention is to focus on diagnostics following the Company’s exit from China operations. The transaction could be a complete divestment or entail an upfront access to technology fee, milestone payments and royalties. We remain committed to securing the best deal for shareholders and are well into a competitive process to that end with a number of interested parties.

AGX-1211

Agenix also has the elements to develop a rapid point of care diagnostic test for active tuberculosis (TB). Agenix owns 100% of AGX1211, a molecular diagnostic for the detection of active TB. AGX1211 is a potential analyte for our DiagnostIQ® human health diagnostic platform.

AGX1211 detects an essential protein found in M. tuberculosis, required for optimal growth of the bacterium that is highly expressed during active infection. However, a concentration process to enrich the analyte material, typically sputum, is required for this technology to reach commercial applicability.

The development of a point of care test that is rapid and affordable that can be used at any location where health care is provided and does not require electricity or specialist training is the ideal TB diagnostic tool that would revolutionise TB control efforts worldwide.

Page 4 of 7

Quarterly Update and Appendix 4C

Agenix Limited 23 July 2013

According to the World Health Organization, TB kills 3 people per minute and in 2009, 1.7 million people died from TB. TB is among the three greatest causes of death among women aged 15-44. According to The Global Fund to Fight AIDS, Tuberculosis and Malaria in 2011 there were 8.7 million new cases of TB. Our primary focus is on partnering the AGX1211 assay with a sputum concentration technology then outlicensing; a business development approach.

Confidence in our strategy

In February, the respected Melbourne-based broker Lodge Partners issued a research note to clients highlighting the investment opportunity in Agenix. The report concluded: "It is rare to find a micro-cap with a quality phase III asset like ThromoView (TVB). Back in 2009, Prima Biomed (ASX: PRR) and its ovarian cancer vaccine, CVac, were in a similar position to that which Agenix finds itself now. The tide turned for Prima when a drug similar to CVac produced some very promising results. The (recent) journal articles may prove to be the beginning of the turning point for Agenix and TBV."

The Board and management are confident and focused on delivering on these commercial milestones in a disciplined and strategic manner.

Yours faithfully,

==> picture [137 x 42] intentionally omitted <==

Nicholas Weston

Chairman & Chief Executive T:+61 1300 132 551 www.agenix.com

Page 5 of 7